Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EYPT Stock Forecast 2025-2026
$17.74
Current Price
$1.47B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EYPT Price Targets
+283.3%
To High Target of $68.00
+86.0%
To Median Target of $33.00
+12.7%
To Low Target of $20.00
EYPT Price Momentum
+19.6%
1 Week Change
+58.3%
1 Month Change
+103.7%
1 Year Change
+138.1%
Year-to-Date Change
-0.4%
From 52W High of $17.82
+353.7%
From 52W Low of $3.91
📊 TOP ANALYST CALLS
Did EYPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if EyePoint is one of their latest high-conviction picks.
Latest EYPT Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, EYPT has a bullish consensus with a median price target of $33.00 (ranging from $20.00 to $68.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $17.74, the median forecast implies a 86.0% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Graig Suvannavejh at Mizuho, suggesting a 12.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYPT Analyst Ratings
13
Buy
0
Hold
0
Sell
EYPT Price Target Range
Low
$20.00
Average
$33.00
High
$68.00
Current: $17.74
Latest EYPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | RBC Capital | Lisa Walter | Outperform | Maintains | $39.00 |
| Aug 7, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $27.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $23.00 |
| Jun 17, 2025 | RBC Capital | Lisa Walter | Outperform | Initiates | $28.00 |
| May 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $22.00 |
| May 16, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $26.00 |
| May 8, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $27.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $22.00 |
| Mar 6, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Feb 6, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Jan 7, 2025 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $33.00 |
| Dec 5, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $22.00 |
| Nov 11, 2024 | Baird | Outperform | Maintains | $33.00 | |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $22.00 |
| Nov 8, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $33.00 |
| Oct 29, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $28.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $30.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $18.00 |
| Aug 28, 2024 | Jefferies | Kambiz Yazdi | Buy | Initiates | $15.00 |
| Aug 13, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $29.00 |
EyePoint Pharmaceuticals Inc. (EYPT) Competitors
The following stocks are similar to EyePoint based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EyePoint Pharmaceuticals Inc. (EYPT) Financial Data
EyePoint Pharmaceuticals Inc. has a market capitalization of $1.47B with a P/E ratio of -7.6x. The company generates $42.34M in trailing twelve-month revenue with a 91.4% profit margin.
Revenue growth is -90.8% quarter-over-quarter, while maintaining an operating margin of -6,420.8% and return on equity of -98.2%.
Valuation Metrics
Market Cap
$1.47B
Enterprise Value
$1.20B
P/E Ratio
-7.6x
PEG Ratio
-0.1x
Price/Sales
32.7x
Growth & Margins
Revenue Growth (YoY)
-90.8%
Gross Margin
+25.4%
Operating Margin
-6,420.8%
Net Margin
+91.4%
EPS Growth
-90.8%
Financial Health
Cash/Price Ratio
+13.9%
Current Ratio
7.2x
Debt/Equity
11.6x
ROE
-98.2%
ROA
-49.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
EyePoint Pharmaceuticals Inc. (EYPT) Business Model
About EyePoint Pharmaceuticals Inc.
What They Do
Develops innovative ophthalmic biopharmaceutical products.
Business Model
The company focuses on developing and commercializing ophthalmic products, particularly for serious eye disorders. It generates revenue through the sale of its sustained-release treatments, which are designed to improve patient outcomes by ensuring consistent therapeutic levels over time, as well as through collaborations with other eye care companies.
Additional Information
EyePoint Pharmaceuticals is based in Watertown, Massachusetts, and actively participates in the biotechnology and healthcare sectors. Its commitment to addressing unmet medical needs in ophthalmology positions it as a key player in advancing therapeutic research and expanding access to solutions for visual impairment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
165
CEO
Dr. Jay S. Duker M.D.
Country
United States
IPO Year
2018
Website
eyepointpharma.comEyePoint Pharmaceuticals Inc. (EYPT) Latest News & Analysis
Latest News
Quick Summary
EyePoint Pharmaceuticals granted non-statutory stock options to new employees as inducement awards, compliant with NASDAQ Listing Rule 5635(c)(4), to enhance talent acquisition.
Why It Matters
EyePoint Pharmaceuticals' grant of stock options may signal confidence in growth and attract talent, potentially impacting future performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
EyePoint Pharmaceuticals reports no protocol changes for LUGANO and LUCIA trials. Safety data for DURAVYU shows no issues; topline results expected mid-2026.
Why It Matters
Stable safety data and no protocol changes in key trials for DURAVYU enhance investor confidence, indicating potential positive outcomes and advancing timelines for crucial clinical results.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
EyePoint Pharmaceuticals will hold its Q3 2025 earnings call on November 5, 2025, at 8:30 AM EST, featuring key executives and analysts from major financial firms.
Why It Matters
EyePoint Pharmaceuticals' Q3 earnings call indicates upcoming financial performance insights, which could impact stock valuation and investor sentiment regarding the company's growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
1 month ago
Quick Summary
Phase 3 LUGANO and LUCIA trials for DURAVYU™ in wet AMD are fully enrolled, with data expected to be released starting mid-2026.
Why It Matters
The successful enrollment of trials for DURAVYU™ signals potential future revenue from wet AMD treatment, influencing stock valuations and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
EyePoint Pharmaceuticals (EYPT) reported a quarterly loss of $0.85 per share, worse than the estimated loss of $0.77, and a decline from a loss of $0.54 per share a year prior.
Why It Matters
EyePoint Pharmaceuticals' larger-than-expected quarterly loss signals potential operational challenges, which may affect investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
EyePoint Pharmaceuticals (NASDAQ: EYPT) will participate in the Guggenheim's 2nd Annual Healthcare Innovation Conference on November 10, 2025, at 10:30 a.m.
Why It Matters
EyePoint Pharmaceuticals' participation in key healthcare conferences can enhance visibility, attract investors, and potentially drive stock performance through increased interest in its innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EYPT Stock
What is EyePoint Pharmaceuticals Inc.'s (EYPT) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, EyePoint Pharmaceuticals Inc. (EYPT) has a median price target of $33.00. The highest price target is $68.00 and the lowest is $20.00.
Is EYPT stock a good investment in 2026?
According to current analyst ratings, EYPT has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EYPT stock?
Wall Street analysts predict EYPT stock could reach $33.00 in the next 12 months. This represents a 86.0% increase from the current price of $17.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is EyePoint Pharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing ophthalmic products, particularly for serious eye disorders. It generates revenue through the sale of its sustained-release treatments, which are designed to improve patient outcomes by ensuring consistent therapeutic levels over time, as well as through collaborations with other eye care companies.
What is the highest forecasted price for EYPT EyePoint Pharmaceuticals Inc.?
The highest price target for EYPT is $68.00 from at , which represents a 283.3% increase from the current price of $17.74.
What is the lowest forecasted price for EYPT EyePoint Pharmaceuticals Inc.?
The lowest price target for EYPT is $20.00 from Graig Suvannavejh at Mizuho, which represents a 12.7% increase from the current price of $17.74.
What is the overall EYPT consensus from analysts for EyePoint Pharmaceuticals Inc.?
The overall analyst consensus for EYPT is bullish. Out of 14 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are EYPT stock price projections?
Stock price projections, including those for EyePoint Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:01 PM UTC